Skip to content
Balaxi Pharmaceuticals logo

Balaxi Pharmaceuticals

BALAXI NSE
₹20.50 +0.24 (+1.18%)
P/E
45.56
View as Markdown
MCP
Close 4 Nov 2026 ₹20.50 −21.76 −51.5% 1Y
Start ₹42.26

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
3.47%
Debt to Equity
0.23
EPS (TTM)
₹0.45
Book Value
₹45.12
Market Cap
—
P/E (TTM)
45.56
P/B
0.45
ROE
0.59%
Dividend Yield
2.47%
EBITDA
₹11.30 Cr
52W High
₹42.90
52W Low
₹15.20
Day Range
₹19.75 – ₹21.00
Volume
7,784

Peer Comparison

Healthcare › Pharmaceuticals

Balaxi Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Balaxi Pharmaceuticals (this company)
₹20.5045.56₹112 Cr0.452.47%0.59%3.47%₹280 Cr₹2 Cr
Median 8 companies₹1,587.7042.19₹1,25,337 Cr4.570.70%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

43 Weak

Data confidence 100/100

Category scores

Quality
48
Average
Returns, margins, earnings quality 22% weight
Valuation
42
Weak
Cheap vs sector & own history 24% weight
Growth
29
Poor
Sales & profit trajectory 9% weight
Financial Health
46
Average
Solvency, leverage, coverage 9% weight
Momentum
24
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.50 times its book value

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 3.15% over past five years.
  • Company has a low return on equity of -3.58% over last 3 years.
  • Earnings include an other income of Rs.3.62 Cr.
  • Company has high debtors of 184 days.
  • Promoter holding has decreased over last 3 years: -5.23%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1153
OscillatorsBearish351
Moving AveragesStrong Bearish802

Key readings

RSI (14)
42.19
Neutral
MACD (12,26,9)
−0.76
Bearish
SMA (50)
22.37
Bearish
SMA (200)
23.14
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+3.17%
3Y−7.03%
1Y−7.85%
TTM−5.90%

Net profit

Net profit growth by window
5Y−51.69%
3Y−72.09%
1Y−96.00%
TTM−87.13%

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YTurned negative
1YOutflow narrowed by ₹31 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−14.91 pp
3Y−13.26 pp
1Y−9.27 pp
TTM−7.29 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹14.00 Cr
Mar 2020₹46.00 Cr
Mar 2021₹231 Cr
Mar 2022₹279 Cr
Mar 2023₹336 Cr
Mar 2024₹241 Cr
Mar 2025₹293 Cr
Mar 2026₹270 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹2.00 Cr
Mar 2020₹6.00 Cr
Mar 2021₹38.00 Cr
Mar 2022₹48.00 Cr
Mar 2023₹46.00 Cr
Mar 2024−₹2.00 Cr
Mar 2025₹25.00 Cr
Mar 2026₹1.00 Cr

Quarterly Results

₹ Cr
BALAXI quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
65.96
54.72
60.79
59.83
65.62
77.38
73.29
76.27
70.74
56.18
72.54
70.71
80.68
Expenses
57.12
43.96
47.14
46.36
55.53
66.79
69.3
63.72
66.58
55.02
69.45
70.59
76.02
Operating Profit
8.84
10.76
13.65
13.47
10.09
10.59
3.99
12.55
4.16
1.16
3.09
0.12
4.66
OPM %
13.4%
19.66%
22.45%
22.51%
15.38%
13.69%
5.44%
16.45%
5.88%
2.06%
4.26%
0.17%
5.78%
Other Income
−47.68
5.93
1.51
−0.7
−1.85
−4.11
3.94
−1.69
−1.78
1.59
0.1
2.92
−0.99
Interest
0.29
0.37
0.41
0.61
0.37
0.45
1.38
0.74
1.01
0.89
1.02
0.99
0.73
Depreciation
0.29
0.66
0.48
0.67
0.49
0.46
0.48
0.46
0.46
0.48
0.56
0.65
0.85
PBT
−39.41
15.66
14.27
11.49
7.37
5.56
6.07
9.66
0.91
1.38
1.61
1.4
2.09
Tax %
4.9%
7.92%
4.77%
4.87%
12.06%
17.41%
11.7%
10.56%
67.03%
84.06%
80.75%
56.43%
38.28%
Net Profit
−41.34
14.43
13.59
10.93
6.48
4.59
5.36
8.64
0.29
0.21
0.31
0.61
1.3
EPS (₹)
−8.07
2.82
2.65
2.01
1.17
0.83
0.97
1.57
0.05
0.04
0.06
0.11
0.24

Profit & Loss

₹ Cr
BALAXI profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
14
46
231
279
336
241
293
270
280
Expenses
12
37
189
229
279
197
254
261
271
Operating Profit
2
8
43
51
57
45
38
10
9
OPM %
11%
18%
18%
18%
17%
18%
13%
3.5%
3.2%
Other Income
1
1
2
5
3
−38
−4
3
4
Interest
0
0
0
1
1
3
4
5
4
Depreciation
0
0
0
1
2
2
2
2
3
PBT
2
9
44
55
57
2
29
5
6
Tax %
19%
31%
14%
13%
19%
219%
13%
73%
—
Net Profit
2
6
38
48
46
−2
25
1
2
EPS (₹)
1.3
1.22
7.63
9.53
9.03
−0.44
4.54
0.26
0.45
Div. Payout %
0%
0%
0%
1%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
BALAXI balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
10
10
10
10
11
11
11
Reserves
0
18
55
103
173
190
221
238
Borrowings
0
0
4
4
13
19
53
58
Other Liabilities
3
8
31
60
43
38
25
30
Total Liabilities
6
36
100
176
240
258
310
337
Fixed Assets
0
0
2
29
41
41
41
82
CWIP
0
0
0
1
3
2
22
0
Investments
0
0
3
0
0
0
0
0
Other Assets
6
36
94
147
195
215
247
255
Total Assets
6
36
100
176
240
258
310
337

Cash Flow

₹ Cr
BALAXI cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−2
−14
0
34
6
5
−35
−4
Investing
0
0
−6
−28
−11
−1
−22
−21
Financing
0
18
4
0
26
30
34
0
Net Cash Flow
−2
4
−2
6
21
34
−23
−25
Free Cash Flow
−2
−14
−3
7
−9
4
−57
−25
CFO/OP
−97
−161
6
78
32
26
−83
2

Ratios

BALAXI financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
147
238
121
36
57
84
138
184
Inventory Days
—
9
29
184
189
233
173
202
Days Payable
—
64
53
92
62
82
36
51
Cash Conversion Cycle
147
183
97
129
184
235
275
335
Working Capital Days
82
181
91
92
122
142
186
236
ROCE %
—
57%
93%
60%
37%
21%
13%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Balaxi Pharmaceuticals insights

57 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 65.99%
  • Public 24.29%
  • Others 7.16%
  • DIIs 2.56%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: FIIs and Others. Not available separately for this quarter: the holding is recorded inside Others, so both are left blank rather than shown at a wrong split.

Documents

  • Q1 FY27 concall · Aug 2026
    PPT
  • Concall · May 2026
    PPT
  • Q3 FY26 concall · Jan 2026
    PPT
  • Q2 FY26 concall · Nov 2025
    PPT
  • Q1 FY26 concall · Aug 2025
    PPT

Frequently Asked Questions about Balaxi Pharmaceuticals

What does Balaxi Pharmaceuticals Ltd do?
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.
Where is Balaxi Pharmaceuticals Ltd (BALAXI) listed?
Balaxi Pharmaceuticals Ltd trades as BALAXI on the NSE.
Which sector does Balaxi Pharmaceuticals Ltd belong to?
Balaxi Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd trades at a PE ratio of 45.56 as of 4 Nov 2026, on earnings per share of ₹0.45, against a book value of ₹45.12 per share.
What is the 52-week high and low of Balaxi Pharmaceuticals Ltd?
Over the last 52 weeks Balaxi Pharmaceuticals Ltd has traded between ₹15.2 and ₹42.9 as of 4 Nov 2026.
Does Balaxi Pharmaceuticals Ltd pay dividends?
Balaxi Pharmaceuticals Ltd has a dividend yield of 2.47%.
What is the Return on Equity (ROE) of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd reported a return on equity of 0.59%. Its debt-to-equity ratio is 0.23.

Company Information

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.

Website balaxiventures.in
Listed 30 Nov 2015
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BALAXI.md for Balaxi Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month